Literature DB >> 1569152

Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement.

C J Greenbaum1, J P Palmer, B Kuglin, H Kolb.   

Abstract

Insulin autoantibodies (IAA) have been identified in newly diagnosed insulin-dependent diabetes mellitus (IDDM) patients and in individuals at high risk of developing the disease. However, the literature is not in agreement regarding the prevalence, significance, and predictive value of IAA. Previous workshops have shown that certain sera give markedly different results depending upon assay methodology and, therefore, have suggested that these discrepancies may be due to variations in the assay methodologies used: either the fluid phase RIA or the solid phase enzyme-linked immunosorbent assay (ELISA). Sera from controls (n = 61), newly diagnosed IDDM patients (n = 30), healthy subjects who later became diabetic (n = 8), and first degree relatives of diabetic probands (n = 22) were randomly numbered and sent without category identification to 19 RIA and 10 ELISA laboratories. Each laboratory's raw data from the control sera were used to determine the cut-off point for positive (3 SD above the mean of control sera) in the disease relevant categories. RIA and ELISA methods were comparable in obtaining a low frequency of IAA in control sera. However, the laboratories using RIA methods found a much higher percentage of sera to be IAA positive among both newly diagnosed patients and healthy individuals who later developed diabetes than laboratories using ELISA methods (P less than 0.005). In contrast, there was considerable overlap in the percentage of sera from first degree relatives found positive by both assays. These data strongly suggest that IAA measured by RIA methodology are more disease related than those measured by ELISA methods. Consequently, RIA assays or assays proven to perform as well should be used to measure IAA associated with IDDM.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569152     DOI: 10.1210/jcem.74.5.1569152

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  46 in total

Review 1.  Antigen-specific responses in autoimmunity and tolerance.

Authors:  J W Thomas
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies.

Authors:  M Schlosser; P W Mueller; C Törn; E Bonifacio; P J Bingley
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

Review 3.  Prediction and prevention of type I diabetes.

Authors:  R Gianani; G S Eisenbarth
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

Review 4.  Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus.

Authors:  Elena Pipi; Marietta Marketou; Alexandra Tsirogianni
Journal:  World J Diabetes       Date:  2014-08-15

Review 5.  Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease.

Authors:  Juha Grönholm; Michael J Lenardo
Journal:  Clin Immunol       Date:  2014-12-05       Impact factor: 3.969

6.  Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis.

Authors:  S Martin; J Kardorf; B Schulte; E F Lampeter; F A Gries; I Melchers; R Wagner; J Bertrams; B O Roep; A Pfützner
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

7.  Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.

Authors:  H Viskari; J Paronen; P Keskinen; S Simell; B Zawilinska; I Zgorniak-Nowosielska; S Korhonen; J Ilonen; O Simell; A-M Haapala; M Knip; H Hyöty
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

8.  Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?

Authors:  Alexandra Fouts; Laura Pyle; Liping Yu; Dongmei Miao; Aaron Michels; Jeffrey Krischer; Jay Sosenko; Peter Gottlieb; Andrea K Steck
Journal:  Diabetes Care       Date:  2016-07-25       Impact factor: 19.112

Review 9.  Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?

Authors:  C Betterle; F Lazzarotto; F Presotto
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  Autoimmune pancreatitis: the emerging role of serologic biomarkers.

Authors:  John W Wiley; Massimo Pietropaolo
Journal:  Diabetes       Date:  2009-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.